

# G V Ramesh Prasad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7936015/publications.pdf>

Version: 2024-02-01

97  
papers

5,227  
citations

136950

32  
h-index

88630

70  
g-index

98  
all docs

98  
docs citations

98  
times ranked

6460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-transplant outcomes in recipients of living donor kidneys and intended recipients of living donor kidneys. BMC Nephrology, 2022, 23, 97.	1.8	5
2	Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210803.	1.1	5
3	Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study. Transplantation, 2022, 106, 1622-1628.	1.0	15
4	Evaluation of left atrial remodeling in kidney transplant patients using cardiac magnetic resonance imaging. Journal of Nephrology, 2021, 34, 851-859.	2.0	3
5	Impact of Perioperative Complications on Living Kidney Donor Health-Related Quality of Life and Mental Health: Results From a Prospective Cohort Study. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110374.	1.1	1
6	Cardiac MRI assessment of the right ventricle pre-and post-kidney transplant. International Journal of Cardiovascular Imaging, 2021, 37, 1757-1766.	1.5	3
7	Enhancing clinical judgement in virtual care for complex chronic disease. Journal of Evaluation in Clinical Practice, 2021, 27, 677-683.	1.8	6
8	Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555.	3.5	4
9	Managing cardiovascular disease risk in South Asian kidney transplant recipients. World Journal of Transplantation, 2021, 11, 147-160.	1.6	1
10	Retrospective Analysis of Tacrolimus Inpatient Variability as a Measure of Medication Adherence. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110217.	1.1	5
11	The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients. Frontiers in Cardiovascular Medicine, 2021, 8, 763389.	2.4	2
12	Medical good luck and medical bad luck. Journal of Evaluation in Clinical Practice, 2020, 26, 465-470.	1.8	3
13	A RAND-Modified Delphi on Key Indicators to Measure the Efficiency of Living Kidney Donor Candidate Evaluations. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1464-1473.	4.5	10
14	The First North American Experience Using Glycosorb Immunoabsorption Columns for Blood Groupâ€“Incompatible Kidney Transplantation. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096258.	1.1	3
15	Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811985771.	1.1	17
16	Growth differentiation factor 15 is decreased by kidney transplantation. Clinical Biochemistry, 2019, 73, 57-61.	1.9	13
17	Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811985053.	1.1	7
18	Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infectious Diseases, 2019, 19, 311.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Nonreimbursed Costs Incurred by Living Kidney Donors: A Case Study From Ontario, Canada. <i>Transplantation</i> , 2019, 103, e164-e171.	1.0	16
20	Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. <i>American Journal of Transplantation</i> , 2019, 19, 1730-1744.	4.7	19
21	Monitoring Kidney Dysfunction in Kugelberg-Welander Syndrome. <i>American Journal of Case Reports</i> , 2019, 20, 441-446.	0.8	1
22	Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation. <i>Annals of Transplantation</i> , 2019, 24, 100-107.	0.9	5
23	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018, 34, 506-525.	1.7	474
24	Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2018, 72, 483-498.	1.9	33
25	Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 83.	3.3	24
26	Financial Costs Incurred by Living Kidney Donors: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2847-2857.	6.1	45
27	Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811880997.	1.1	13
28	Understanding the sex disparity in living kidney donation. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 999-1004.	1.8	14
29	CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 23-33.	0.7	36
30	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017, 33, 557-576.	1.7	269
31	Role of Magnetic Resonance Elastography as a Noninvasive Measurement Tool of Fibrosis in a Renal Allograft: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 1555-1559.	0.6	11
32	The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes. <i>Transplantation</i> , 2017, 101, 2213-2217.	1.0	4
33	Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival. <i>Kidney International</i> , 2016, 89, 1119-1124.	5.2	24
34	The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients. <i>Transplantation Research</i> , 2016, 5, 2.	1.5	7
35	Reduction in New-Onset Diabetes Mellitus after Renal Transplant with Erythropoietin-Stimulating Agents: A Retrospective Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 114.	1.1	0
36	Distinguishing internal property from external property in kidney transplantation. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 539-543.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
38	Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World Journal of Transplantation, 2016, 6, 125.	1.6	84
39	A moral dilemma argument against clinical trials of incentives for kidney donation. Transplantation Research, 2015, 4, 3.	1.5	1
40	How the creative use of analogies can shape medical practice. Journal of Evaluation in Clinical Practice, 2015, 21, 455-460.	1.8	2
41	New-onset diabetes mellitus after kidney transplantation: Current status and future directions. World Journal of Diabetes, 2015, 6, 445.	3.5	86
42	Gout After Living Kidney Donation: A Matched Cohort Study. American Journal of Kidney Diseases, 2015, 65, 925-932.	1.9	45
43	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
44	Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation. Transplant International, 2015, 28, 79-88.	1.6	20
45	Screening for cardiovascular disease before kidney transplantation. World Journal of Transplantation, 2015, 5, 276.	1.6	22
46	Metabolic syndrome and chronic kidney disease: Current status and future directions. World Journal of Nephrology, 2014, 3, 210.	2.0	118
47	A Clinical and Pathological Variant of Acute Transplant Glomerulopathy. Case Reports in Pathology, 2014, 2014, 1-5.	0.3	1
48	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
49	Living kidney donor estimated glomerular filtration rate and recipient graft survival. Nephrology Dialysis Transplantation, 2014, 29, 188-195.	0.7	16
50	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2014, 63, 869-887.	1.9	31
51	A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. Transplantation Research, 2013, 2, 1.	1.5	23
52	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	1.7	163
53	A comparison of the extended-release and standard-release formulations of tacrolimus in kidney transplant recipients: a 12-month outcome study. CKJ: Clinical Kidney Journal, 2013, 6, 45-49.	2.9	11
54	Adiponectin in renal disease – a review of the evidence as a risk factor for cardiovascular and all-cause mortality. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 218-231.	6.1	4

#	ARTICLE	IF	CITATIONS
55	Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. CKJ: Clinical Kidney Journal, 2012, 5, 124-129.	2.9	6
56	Acute dialysis risk in living kidney donors. Nephrology Dialysis Transplantation, 2012, 27, 3291-3295.	0.7	32
57	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	1.7	173
58	Bone and Mineral Metabolism and Fibroblast Growth Factor 23 Levels After Kidney Donation. American Journal of Kidney Diseases, 2012, 59, 761-769.	1.9	48
59	Fracture Risk in Living Kidney Donors: A Matched Cohort Study. American Journal of Kidney Diseases, 2012, 59, 770-776.	1.9	40
60	Ambulatory blood pressure monitoring in solid organ transplantation. Clinical Transplantation, 2012, 26, 185-191.	1.6	16
61	Framingham Risk Score and Novel Cardiovascular Risk Factors Underpredict Major Adverse Cardiac Events in Kidney Transplant Recipients. Transplantation, 2011, 92, 183-189.	1.0	52
62	Accepting Kidneys from Older Living Donors: Impact on Transplant Recipient Outcomes. American Journal of Transplantation, 2011, 11, 743-750.	4.7	51
63	Organ donation after cardiac death: donor and recipient outcomes after the first three years of the Ontario experience. Canadian Journal of Anaesthesia, 2011, 58, 599-605.	1.6	38
64	South Asian Ethnicity as a Risk Factor for Major Adverse Cardiovascular Events after Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 204-211.	4.5	22
65	Policy Statement of Canadian Society of Transplantation and Canadian Society of Nephrology on Organ Trafficking and Transplant Tourism. Transplantation, 2010, 90, 817-820.	1.0	28
66	Canadian Society of Transplantation and Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Kidney Diseases, 2010, 56, 219-246.	1.9	44
67	Twenty four-hour ambulatory blood pressure profiles 12 months post living kidney donation. Transplant International, 2010, 23, 771-776.	1.6	10
68	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I " blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	1.7	170
69	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 " therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	1.7	191
70	A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada. Journal of Nephrology, 2010, 23, 274-81.	2.0	7
71	Association of Uric Acid With Inflammation, Progressive Renal Allograft Dysfunction and Post-Transplant Cardiovascular Risk. American Journal of Cardiology, 2009, 103, 867-871.	1.6	42
72	Microalbuminuria post renal transplantation: relation to cardiovascular risk factors and C reactive protein. Clinical Transplantation, 2009, 23, 313-320.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Hypertension in dialysis and kidney transplant patients. <i>Canadian Journal of Cardiology</i> , 2009, 25, 309-314.	1.7	21
74	Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. <i>Clinical Nephrology</i> , 2009, 71, 140-6.	0.7	20
75	A Prospective Observational Study of Changes in Renal Function and Cardiovascular Risk Following Living Kidney Donation. <i>Transplantation</i> , 2008, 86, 1315-1318.	1.0	26
76	Outcomes of Commercial Renal Transplantation: A Canadian Experience. <i>Transplantation</i> , 2006, 82, 1130-1135.	1.0	86
77	Meta-Analysis: Risk for Hypertension in Living Kidney Donors. <i>Annals of Internal Medicine</i> , 2006, 145, 185.	3.9	341
78	The role of dietary cations in the blood pressure of renal transplant recipients. <i>Clinical Transplantation</i> , 2006, 20, 37-42.	1.6	14
79	Psychosocial Health of Living Kidney Donors: A Systematic Review. <i>American Journal of Transplantation</i> , 2006, 6, 2965-2977.	4.7	235
80	Minimal Change Disease in Association With Fire Coral ( <i>Millepora</i> Species) Exposure. <i>American Journal of Kidney Diseases</i> , 2006, 47, e15-e16.	1.9	17
81	Gastrointestinal-Specific Patient-Reported Outcome Instruments Differentiate Between Renal Transplant Patients With or Without GI Complications. <i>Transplantation Proceedings</i> , 2005, 37, 846-849.	0.6	30
82	A Numerical Scale Comparison of Renal Transplant Recipient Experience with and Opinions about Calcineurin Inhibitors. <i>Nephron Clinical Practice</i> , 2004, 97, c35-c40.	2.3	7
83	Diltiazem use in tacrolimus-treated renal transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 425-430.	1.5	19
84	Reduced Incidence of New-Onset Diabetes Mellitus after Renal Transplantation with 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins). <i>American Journal of Transplantation</i> , 2004, 4, 1897-1903.	4.7	55
85	Death with graft function in elderly patients after cadaveric renal transplantation: Effect of waiting time. <i>Transplantation Proceedings</i> , 2004, 36, 2985-2987.	0.6	6
86	Community-acquired West Nile virus infection in solid-organ transplant recipients. <i>Transplantation</i> , 2004, 77, 399-402.	1.0	123
87	Recurrence of type III membranoproliferative glomerulonephritis after renal transplantation. <i>Clinical Nephrology</i> , 2004, 61, 80.	0.7	5
88	Renal transplant recipient attitudes toward steroid use and steroid withdrawal. <i>Clinical Transplantation</i> , 2003, 17, 135-139.	1.6	55
89	Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. <i>Kidney International</i> , 2003, 63, 360-364.	5.2	33
90	Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction1. <i>Transplantation</i> , 2003, 75, 209-216.	1.0	10

#	ARTICLE	IF	CITATIONS
91	A prospective study of the physician effect on blood pressure in renal-transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 996-1000.	0.7	12
92	Statin use and bone mineral density in renal transplant recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1320-1.	4.7	3
93	Rhabdomyolysis due to red yeast rice ( <i>Monascus purpureus</i> ) in a renal transplant recipient. <i>Transplantation</i> , 2002, 74, 1200-1201.	1.0	108
94	Type I membranoproliferative glomerulonephritis in an HIV-infected individual without hepatitis C co-infection. <i>Clinical Nephrology</i> , 2002, 57, 154-157.	0.7	12
95	Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. <i>Clinical Nephrology</i> , 2000, 53, 55-60.	0.7	58
96	Diabetic nephropathy with concurrent hepatitis C virus infection related membranoproliferative glomerulonephritis. <i>Clinical Nephrology</i> , 1999, 51, 50-3.	0.7	4
97	Reconstituted Aquaporin 1 Water Channels Transport CO <sub>2</sub> across Membranes. <i>Journal of Biological Chemistry</i> , 1998, 273, 33123-33126.	3.4	152